The subcutaneous biologics market size is calculated at USD 2.1 billion in 2025 and is expected to reach around USD 5.37 ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

Viking Therapeutics, Inc. progressing rapidly with its Phase 3 VANQUISH trials of VK2735 set to complete enrolment. Learn ...

Eli Lilly ( LLY 0.76%) has been on a tear for the better part of the last decade, but the company has experienced a bit of a ...

Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

J&J announces Tremfya, the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years: Phoenix Tues ...

Claire, a 9-month-old Australian Cattle Dog, was severely burned after being left outside in extreme heat. Now healthy, she ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...

Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® ...

Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net ...